Announcement

Collapse
No announcement yet.

Recombinant hemagglutinin proteins formulated in a novel PELC/CpG adjuvant for H7N9 subunit vaccine development

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Recombinant hemagglutinin proteins formulated in a novel PELC/CpG adjuvant for H7N9 subunit vaccine development

    Antiviral Res. 2017 Sep 22;146:213-220. doi: 10.1016/j.antiviral.2017.09.014. [Epub ahead of print]
    Recombinant hemagglutinin proteins formulated in a novel PELC/CpG adjuvant for H7N9 subunit vaccine development.

    Chen TH1, Liu YY1, Jan JT2, Huang MH3, Spearman M4, Butler M4, Wu SC5.
    Author information

    Abstract

    Humans infected with H7N9 avian influenza viruses can result in severe pneumonia and acute respiratory syndrome with an approximately 40% mortality rate, and there is an urgent need to develop an effective vaccine to reduce its pandemic potential. In this study, we used a novel PELC/CpG adjuvant for recombinant H7HA (rH7HA) subunit vaccine development. After immunizing BALB/c mice intramuscularly, rH7HA proteins formulated in this adjuvant instead of an alum adjuvant elicited higher IgG, hemagglutination-inhibition, and virus neutralizing antibodies in sera; induced higher numbers of H7HA-specific IFN-γ-secreting T cells and antibody secreting cells in spleen; and provided improved protection against live virus challenges. Our results indicate that rH7HA proteins formulated in PELC/CpG adjuvant can induce potent anti-H7N9 immunity that may provide useful information for H7N9 subunit vaccine development.
    Copyright ? 2017 Elsevier B.V. All rights reserved.


    KEYWORDS:

    Adjuvant; H7N9; PELC/CpG; Subunit vaccine

    PMID: 28947234 DOI: 10.1016/j.antiviral.2017.09.014
Working...
X